A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants With Active Psoriatic Arthritis

Activo, no reclutaFase 3ClinicalTrials.gov

ID: NCT06878404Tipo: INTERVENTIONALInicio: 21 de feb de 2025Fin estimado: 21 de nov de 2028

Traducción no disponible, mostrando original

Resumen

The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Have a diagnosis of psoriatic arthritis (PsA) for at least 3 months before the first administration of study intervention and meet classification criteria for psoriatic arthritis (CASPAR) at screening
Have active PsA as defined by: (a) At least 3 swollen joints and at least 3 tender joints at screening and at baseline (b) C-reactive protein (CRP) greater than or equal to (\>=) 0.1 milligrams per deciliter (mg/dL) at screening from the central laboratory
Have at least 1 of the PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
Have active plaque psoriasis with at least one psoriatic plaque of \>= 2 cm diameter or nail changes consistent with psoriasis
A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (Beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention

Criterios de exclusión

Has previously received any biologic disease-modifying antirheumatic drugs (DMARDs) for PsA or psoriasis
Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic (with the exception of PsA), psychiatric, genitourinary, or metabolic disturbances
Has known allergies, hypersensitivity, or intolerance to icotrokinra or its excipients
Has other inflammatory diseases that might confound the evaluations of benefit of icotrokinra therapy, including but not limited to rheumatoid arthritis (RA), systemic lupus erythematosus, or lyme disease
Participants with fibromyalgia or osteoarthritis symptoms that, in the investigator's opinion, would have potential to interfere with efficacy assessments

Intervenciones

drug

Icotrokinra

Icotrokinra will be administered.

drug

Placebo

Placebo will be administered.

drug

Active reference comparator

Active reference drug will be administered.

Ubicaciones

Arsema

Ciudad de Buenos Aires, Argentina

Cosultorios Reumatologógicos Pampa

Buenos Aires, Argentina

Mindout Research

Buenos Aires, Argentina

Hospital Central Militar Cirujano Mayor Dr Cosme Argerich

Buenos Aires, Argentina

Centro Medico Privado de Reumatologia Tucuman

Ciudad de San Miguel de Tucuman, Argentina

Consultora Integral de Salud SRL

Córdoba, Argentina

MR Medicina Reumatologica

San Fernando, Argentina

Instituto Medico De Alta Complejidad (IMAC)

San Isidro, Argentina

Patrocinadores

PrincipalJanssen Research & Development, LLC

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase 3, Multicenter, Randomized, Double-blind, Placebo... | EligiMed